CANCER RESEARCH TECHNOLOGY (CRT), Cancer Research UK’s commercialisation and development arm, and Medivir AB (Nasdaq Stockholm: MVIR) today (Monday) jointly announce a partnership to develop a new class of drugs that has shown promise for treating a range of different cancers, especially breast and pancreatic cancer.